Par Drugs And Chemicals Limited has informed the Exchange about Action(s) initiated or orders passed

SEBI investigationRegulatory & Legal View source PDF Explain this filing

PAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.6%Reaction day

₹96.01

prior close

₹96.50

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.8%+1.2% vs market

Pharmaceuticals peers, median of 151sector-1.7%+1.1% vs sector

On the reaction day the stock moved 1.2 pts more than Nifty Microcap 250 and 1.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

-0.5

15m

-0.5

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.6-1.8+1.2-1.7+1.1

Next day

+0.8-1.5+2.4-1.0+1.8

-0.0-1.3+1.3-1.2+1.2

+1.6-0.8+2.3-0.9+2.5

+1.6+1.1+0.5+0.3+1.3

-0.8+1.1-2.0+0.2-1.1

-0.5+2.5-3.1+1.3-1.9

15d

-2.4+3.2-5.6+2.0-4.3

+16.1+4.1+12.1+3.4+12.7

+5.2+0.5+4.7-0.1+5.3

+17.3+2.8+14.5+0.9+16.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 151Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Par Drugs and Chemicals informed the exchange that its Promoter and Independent Director met with SEBI's Corporation Finance Investigation Department officials on June 18, 2025 in Mumbai. The meeting was in connection with the company's earlier February 14, 2025 announcement about a slump sale of its existing establishment (land, building, plant & machinery, and specific current assets/liabilities) to Phal-Jig Fine Chemicals Private Limited. The management made representations before SEBI, and the regulator indicated that a formal communication seeking further information and clarifications will be issued via email. The company stated that no violation or contravention has been alleged and there is no financial or operational impact on the listed entity at this stage.

Likely market impact

The development signals regulatory scrutiny of the slump sale transaction but is not yet adverse. Investors should watch for the formal SEBI communication, which could bring clarity on whether further action is warranted. Short-term sentiment may be cautious given the ongoing inquiry.